SCHEDULE: T. Rowe Price Discloses 10.6% Stake in Replimune Group

Sentiment:

Beneficial Ownership Disclosure


T. Rowe Price Associates, Inc. has reported a 10.6% beneficial ownership stake in Replimune Group Inc. common stock as of September 30, 2025.

Summary

  • T. Rowe Price Associates, Inc. beneficially owns 8,306,757 shares of Replimune Group Inc. common stock.
  • This ownership represents 10.6% of the total class of securities.
  • T. Rowe Price Associates, Inc. holds sole voting power over 8,125,515 shares.
  • T. Rowe Price Associates, Inc. holds sole dispositive power over 8,306,433 shares.
  • The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 7

Explanation: The filing indicates a significant and passive institutional investment by T. Rowe Price, which is generally viewed as a positive signal of confidence in the company's long-term prospects, without any negative disclosures.

Positives

  • A major institutional investor, T. Rowe Price Associates, Inc., holds a significant 10.6% stake, indicating institutional confidence in Replimune Group Inc.

Future Outlook

NA

Industry Context

The disclosure of a significant stake by a prominent investment adviser like T. Rowe Price in a biotechnology company such as Replimune Group Inc. can signal institutional interest and potential long-term investment thesis within the sector, often viewed positively by the market.

Stakeholder Impact

  • Shareholders may view the significant institutional ownership by T. Rowe Price as a positive indicator of the company's value and future potential.

Key Dates

DateDescription
09/30/2025Date of event which requires filing of this statement (reporting period end date)
11/14/2025Signature date of the Schedule 13G Amendment No. 7 filing

Keywords

Replimune Group Inc., T. Rowe Price Associates Inc., Beneficial Ownership, Schedule 13G, Common Stock, Institutional Investor, Equity Stake

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.